| Name | Title | Contact Details |
|---|
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Ultivue develops innovative reagent-based solutions that maximize the biological information available from cells and tissue samples. The company`s technology is being used to elucidate biological pathways and to validate clinically-relevant biomarkers. Ultivue is based in Cambridge, MA. Our culture provides an exceptional work environment fostering innovation and collaboration to make a difference collectively. Ultivue`s employees are bright, flexible, and driven to create meaningful impact through our work. We work at a fast pace, but support each other achieve the work/life balance that helps us thrive as a company. Our entrepreneurial culture relies on contributions and input from all. Our bench of experienced managers provides mentoring and support to ensure front line staff make the most of their unique talents and energy.
EdiGENE Corporation is an emerging biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo.
Seattle Biomedical Research Institute is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Priovant Therapeutics is a clinical stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.